Morgan Stanley has reiterated OVERWEIGHT rating on Lupin and has revised EPS expectations upwards for FY 13 and FY 14. In a report it has said,
...on its earnings momentum (2-year EPS CAGR: 29% vs. industry’s 18%), driven by all-around performance (US, India, Japan, South Africa) and strong US pipeline. We raise our PT to Rs652, and examine two key investor debates: Suprax and US OC market outlook
FY13 EPS 26.89
FY14 EPS 34.30
Target Rs 652, potential upside of 24% from current levels.
